XENT - Medtronic Intersect ENT said to finalize divestiture plans to help with antitrust concerns

Medtronic (NYSE:MDT), which agreed to purchase Intersect ENT (NASDAQ:XENT) for $1.1B in August, is said to be finalizing plans on potential divestitures in an effort to resolve U.S. antitrust concerns. The parties still expect to complete the deal by the target date of April 30, according to a Dealreporter item from Wednesday.  Details on specific divestitures weren't disclosed, though upfront buyers would likely be needed to appease regulators. An Intersect ENT (XENT) spokesman told Dealreporter that the transaction remains on track to close in April. Recall in November that Intersect ENT received a second request from FTC for planned sale to Medtronic.

For further details see:

Medtronic, Intersect ENT said to finalize divestiture plans to help with antitrust concerns